From: Antitumor efficacy of the Egyptian Scorpion Venom Androctonus Australis: in vitro and in vivo study
Parameter treatment | Hemoglobin (g/dL) | RBC count (× 106/μL) | WBC count (× 103/μL) | Granulocytes (× 103/μL) | Lymphocytes (× 103/μL) | Monocytes (× 103/μL) | Platelet count (× 103/μL) |
---|---|---|---|---|---|---|---|
Normal control | 9.72 ± 0.15 | 6.22 ± 0.07 | 5.08 ± 0.13 | 0.20 ± 0.02 | 4.64 ± 0.23 | 0.41 ± 0.04 | 248.44 ± 11.56 |
EAC control | 6.18* ± 0.53 | 4.12* ± 0.27 | 6.27# ± 0.69 | 0.42# ± 0.08 | 5.24# ± 0.63 | 0.77 ± 0.14 | 254.89 ± 16.33 |
EAC + 1/10 LD50 (0.025 mg/kg BW) | 8.26# ± 0.28 | 5.13# ± 0.29 | 3.57* ± 0.37 | 0.21 ± 0.03 | 2.61* ± 0.30 | 0.31 ± 0.09 | 536.33# ± 23.88 |
EAC + cisplatin (2 mg/kg BW) | 5.98 ± 0.56 | 4.33 ± 0.25 | 5.65# ± 0.49 | 0.26 ± 0.04 | 4.63# ± 0.42 | 0.45 ± 0.03 | 599.00# ± 30.92 |